JJ

Johnson & Johnson

www.jnj.com link_icon

Johnson & Johnson Company Research Report



Company Overview



Name:


Johnson & Johnson

Mission:


To redefine healthcare by connecting the best of Health & Care for every provider, for every patient, for everyone.

Founded:


1886

Founders:


Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson

Key People:


  • Chairman and Chief Executive Officer: Joaquin Duato

  • Executive Vice President, Global Corporate Affairs: Vanessa Broadhurst

  • Executive Vice President, Chief Human Resources Officer: Peter Fasolo, Ph.D.

  • Executive Vice President, Chief Legal Officer: Liz Forminard

  • Executive Vice President, Innovative Medicine, R&D: John C. Reed, M.D., Ph.D.

  • Executive Vice President, Worldwide Chairman, MedTech: Tim Schmid

  • Executive Vice President, Chief Information Officer: James Swanson

  • Executive Vice President, Worldwide Chairman, Innovative Medicine: Jennifer L. Taubert

  • Executive Vice President, Chief Technical Operations and Risk Officer: Kathryn E. Wengel

  • Executive Vice President, Chief Financial Officer: Joseph J. Wolk


Headquarters:


New Brunswick, New Jersey, United States

Number of Employees:


Approximately 130,000 worldwide

Revenue:


No information is available

Known For:


Leading innovations in healthcare across pharmaceuticals, medical devices, and consumer health products.

Products



Pharmaceuticals:


  • TREMFYA: Treats plaque psoriasis, psoriatic arthritis, and ulcerative colitis.

  • Key Features: Dual-acting interleukin-23 inhibitor, high rates of endoscopic remission.


  • RYBREVANT: Treats advanced EGFR-mutated non-small cell lung cancer.

  • Key Features: Targets EGFR mutations, used in combination therapies, significant improvement in progression-free survival.


  • LAZCLUZE: Investigational drug used in combination with RYBREVANT for lung cancer.

  • Key Features: Shows overall survival trends versus osimertinib.


  • Nipocalimab: Under regulatory review to treat antibody positive generalized myasthenia gravis.

  • Key Features: High affinity and specificity to block FcRn, reduces levels of autoantibodies.


Medical Devices:


  • DePuy Synthes: Focuses on orthopaedic devices.

  • Key Features: Advanced orthopaedic devices, educational support for providers, diversity and inclusion initiatives.


  • Teligen System: Surgical technology platform.

  • Key Features: Disposable camera for enhanced visibility during minimally invasive spine surgeries.


Consumer Health:


No information is available

Recent Developments



New Products Launched:


  • TREMFYA: Received FDA approval for ulcerative colitis (September 11, 2024).

  • MatrixSTERNUM Fixation System: Launched by DePuy Synthes (August 29, 2024).


New Features Added:


No information is available

New Partnerships:


  • Johnson & Johnson MedTech: Updated brand identity, unifying Ethicon, DePuy Synthes, Biosense Webster, Abiomed, and CERENOVUS under the Johnson & Johnson MedTech name (September 10, 2024).


Other Notable Developments:


  • Dexamethasone: Reduction in infusion-related reactions for patients with EGFR-mutated non-small cell lung cancer treated with RYBREVANT (September 10, 2024).

  • Johnson & Johnson Acquired Shockwave Medical (April 5, 2024).


Johnson & Johnson continues to innovate across various sectors of healthcare, promoting diversity, equity, and inclusion, while addressing global health inequities and environmental sustainability.




This report summarizes the key information on Johnson & Johnson based on the data provided. For further details or financial information, please refer to the company's official press releases and financial reports.